Related Experiment Video
Updated: Jun 1, 2026
11:19
Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 17, 2011
Pediatric insomnia.
Judith A Owens1, Jodi A Mindell
1Division of Pulmonary and Sleep Medicine, Children's National Medical Center, Washington, DC 20010, USA. owensleep@gmail.com
Pediatric Clinics of North America
|May 24, 2011
Summary
Pediatric insomnia, including bedtime struggles and night wakings, significantly impacts children and families. This review covers causes, diagnosis, and treatments for childhood sleep disorders.
Area of Science:
- Pediatric Sleep Medicine
- Child Psychology
- Clinical Neurology
Background:
- Childhood insomnia is highly prevalent, affecting infants, children, and adolescents.
- Sleep disturbances significantly impair the quality of life for both children and their caregivers.
- Common issues include bedtime resistance, delayed sleep onset, and frequent night wakings.
Purpose of the Study:
- To review the current research and clinical understanding of childhood insomnia.
- To discuss the prevalence, causes, and risk factors associated with pediatric sleep problems.
- To outline the evaluation and treatment strategies for common childhood insomnia types.
Main Methods:
- Literature review of existing research on childhood insomnia.
- Analysis of clinical nosology and diagnostic criteria.
- Synthesis of information on behavioral and pharmacologic treatments.
- Discussion of insomnia in special pediatric populations.
Main Results:
- Childhood insomnia encompasses a range of sleep difficulties with significant impact.
- Etiologic factors are diverse, varying across age groups.
- Effective behavioral and pharmacologic treatments are available.
- Special populations, including those with chronic conditions, present unique challenges.
Conclusions:
- Understanding the multifaceted nature of pediatric insomnia is crucial for effective management.
- Comprehensive evaluation and tailored treatment plans are essential.
- Further research is needed to address insomnia in complex pediatric cases and explore future therapeutic avenues.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:27Insomnia
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...